Sixty-five percent of patients with PHTS express PTEN variants such as deletions, DNA insertions or non-sense variants leading to STOP codons (such as R130X and R233X), resulting in PTEN truncation, which are therefore predicted to cause heterozygous loss of expression. This evidence concerns the gene PTEN and PTEN hamartoma tumor syndrome.